Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma

BACKGROUND: In the Phase 3 REFLECT trial in patients with unresectable hepatocellular carcinoma (uHCC), the multitargeted tyrosine kinase inhibitor, lenvatinib, was noninferior to sorafenib in the primary outcome of overall survival. Post-hoc review revealed imbalances in prognostic variables betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Briggs, Andrew, Daniele, Bruno, Dick, Katherine, Evans, Thomas R. Jeffry, Galle, Peter R., Hubner, Richard A., Lopez, Carlos, Siebert, Uwe, Tremblay, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283323/
https://www.ncbi.nlm.nih.gov/pubmed/32265508
http://dx.doi.org/10.1038/s41416-020-0817-7